This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (945)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Prostate Disease  • Oncology  • Prostate Cancer  • Alert me on articles by topic

Charles R. Pound, MD; Alan W. Partin, MD, PhD; Mario A. Eisenberger, MD; Daniel W. Chan, PhD; Jay D. Pearson, PhD; Patrick C. Walsh, MD

JAMA. 1999;281:1591-1597.

Context  In men who develop an elevated serum prostate-specific antigen level (PSA) after having undergone a radical prostatectomy, the natural history of progression to distant metastases and death due to prostate cancer is unknown.

Objective  To characterize the time course of disease progression in men with biochemical recurrence after radical prostatectomy.

Design  A retrospective review of a large surgical series with median (SD) follow-up of 5.3 (3.7) years (range, 0.5-15 years) between April 1982 and April 1997.

Setting  An urban academic tertiary referral institution.

Patients  A total of 1997 men undergoing radical prostatectomy, by a single surgeon, for clinically localized prostate cancer. None received neoadjuvant therapy, and none had received adjuvant hormonal therapy prior to documented distant metastases.

Main Outcome Measures  After surgery, men were followed up with PSA assays and digital rectal examinations every 3 months for the first year, semiannually for the second year, and annually thereafter. A detectable serum PSA level of at least 0.2 ng/mL was evidence of biochemical recurrence. Distant metastases were diagnosed by radionuclide bone scan, chest radiograph, or other body imaging, which was performed at the time of biochemical recurrence and annually thereafter.

Results  The actuarial metastasis-free survival for all 1997 men was 82% (95% confidence interval, 76%-88%) at 15 years after surgery. Of the 1997 men, 315 (15%) developed biochemical PSA level elevation. Eleven of these underwent early hormone therapy after the recurrence and are not included in the study. Of the remaining 304 men, 103 (34%) developed metastatic disease within the study period. The median actuarial time to metastases was 8 years from the time of PSA level elevation. In survival analysis, time to biochemical progression (P<.001), Gleason score (P<.001), and PSA doubling time (P<.001) were predictive of the probability and time to the development of metastatic disease. An algorithm combining these parameters was constructed to stratify men into risk groups. Once men developed metastatic disease, the median actuarial time to death was 5 years. The time interval from surgery to the appearance of metastatic disease was predictive of time until death (P<.02).

Conclusions  Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy. These data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies.

Author Affiliations: Departments of Urology, The James Buchanan Brady Urological Institute (Drs Pound, Partin, and Walsh), Oncology (Dr Eisenberger), and Pathology (Dr Chan), The Johns Hopkins Medical Institutions, Baltimore, Md; and Department of Epidemiology, Merck Research Laboratories, Blue Bell, Pa (Dr Pearson).

RELATED ARTICLES

Radiation Therapy for Clinically Localized Prostate Cancer: A Multi-institutional Pooled Analysis
William U. Shipley, Howard D. Thames, Howard M. Sandler, Gerald E. Hanks, Anthony L. Zietman, Carlos A. Perez, Deborah A. Kuban, Steven L. Hancock, and Cyndi D. Smith
JAMA. 1999;281(17):1598-1604.
ABSTRACT | FULL TEXT  

Management of Prostate Cancer After Prostatectomy: Treating the Patient, Not the PSA
Howard I. Scher
JAMA. 1999;281(17):1642-1645.
EXTRACT | FULL TEXT  

May 5, 1999
JAMA. 1999;281(17):1663-1664.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Biological Mediators of Effect of Diet and Stress Reduction on Prostate Cancer
Saxe et al.
Integr Cancer Ther 2008;7:130-138.
ABSTRACT  

Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
Gravis et al.
Ann Oncol 2008;19:1624-1628.
ABSTRACT | FULL TEXT  

Systems Pathology Approach for the Prediction of Prostate Cancer Progression After Radical Prostatectomy
Donovan et al.
JCO 2008;26:3923-3929.
ABSTRACT | FULL TEXT  

Genomic Alterations Indicate Tumor Origin and Varied Metastatic Potential of Disseminated Cells from Prostate Cancer Patients
Holcomb et al.
Cancer Res. 2008;68:5599-5608.
ABSTRACT | FULL TEXT  

Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort
Mucci et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1682-1688.
ABSTRACT | FULL TEXT  

Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy
Trock et al.
JAMA 2008;299:2760-2769.
ABSTRACT | FULL TEXT  

Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers
Shariat et al.
Clin. Cancer Res. 2008;14:3785-3791.
ABSTRACT | FULL TEXT  

Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy
Svatek et al.
Clin. Cancer Res. 2008;14:3362-3366.
ABSTRACT | FULL TEXT  

Endorectal and Dynamic Contrast-Enhanced MRI for Detection of Local Recurrence After Radical Prostatectomy
Casciani et al.
Am. J. Roentgenol. 2008;190:1187-1192.
ABSTRACT | FULL TEXT  

External Validation of a Biomarker-Based Preoperative Nomogram Predicts Biochemical Recurrence After Radical Prostatectomy
Shariat et al.
JCO 2008;26:1526-1531.
ABSTRACT | FULL TEXT  

What to Do with an Abnormal PSA Test
Loeb and Catalona
The Oncologist 2008;13:299-305.
ABSTRACT | FULL TEXT  

Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel
Domingo-Domenech et al.
Ann Oncol 2008;19:269-275.
ABSTRACT | FULL TEXT  

Prediction of Prostate-Specific Antigen Recurrence in Men with Long-term Follow-up Postprostatectomy Using Quantitative Nuclear Morphometry
Veltri et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:102-110.
ABSTRACT | FULL TEXT  

Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort
Mucci et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:249-251.
ABSTRACT | FULL TEXT  

Prognostic Significance of p53 and X-ray Repair Cross-complementing Group 1 Polymorphisms on Prostate-Specific Antigen Recurrence in Prostate Cancer Post Radical Prostatectomy
Huang et al.
Clin. Cancer Res. 2007;13:6632-6638.
ABSTRACT | FULL TEXT  

Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
Oudard et al.
Ann Oncol 2007;18:1828-1833.
ABSTRACT | FULL TEXT  

Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era
Shimizu et al.
Jpn J Clin Oncol 2007;0:hym105v1-12.
ABSTRACT | FULL TEXT  

Imaging in Oncology from The University of Texas M. D. Anderson Cancer Center: Diagnosis, Staging, and Surveillance of Prostate Cancer
Kundra et al.
Am. J. Roentgenol. 2007;189:830-844.
ABSTRACT | FULL TEXT  

Identification of Patients With Prostate Cancer Who Benefit From Immediate Postoperative Radiotherapy: EORTC 22911
Van der Kwast et al.
JCO 2007;25:4178-4186.
ABSTRACT | FULL TEXT  

Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy
Bastian et al.
Clin. Cancer Res. 2007;13:5361-5367.
ABSTRACT | FULL TEXT  

Preoperative Plasma HER2 and Epidermal Growth Factor Receptor for Staging and Prognostication in Patients with Clinically Localized Prostate Cancer
Shariat et al.
Clin. Cancer Res. 2007;13:5377-5384.
ABSTRACT | FULL TEXT  

Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy
Alessandro et al.
Endocr Relat Cancer 2007;14:625-632.
ABSTRACT | FULL TEXT  

Targeting Human {gamma}{delta} T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer
Dieli et al.
Cancer Res. 2007;67:7450-7457.
ABSTRACT | FULL TEXT  

Efficiency of Ultrasensitive Prostate-specific Antigen Assay in Diagnosing Biochemical Failure After Radical Prostatectomy
Shimizu et al.
Jpn J Clin Oncol 2007;37:446-451.
ABSTRACT | FULL TEXT  

Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson et al.
JCO 2007;25:2035-2041.
ABSTRACT | FULL TEXT  

Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality
Freedland et al.
JCO 2007;25:1765-1771.
ABSTRACT | FULL TEXT  

Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline
Loblaw et al.
JCO 2007;25:1596-1605.
ABSTRACT | FULL TEXT  

Imaging Prostate Cancer: A Multidisciplinary Perspective
Hricak et al.
Radiology 2007;243:28-53.
ABSTRACT | FULL TEXT  

A Prostate-Specific Antigen-Activated Channel-Forming Toxin as Therapy for Prostatic Disease
Williams et al.
JNCI J Natl Cancer Inst 2007;99:376-385.
ABSTRACT | FULL TEXT  

Treatment of prostate cancer with Ad5/3{Delta}24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo
Rajecki et al.
Molecular Cancer Therapeutics 2007;6:742-751.
ABSTRACT | FULL TEXT  

Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer
Steuber et al.
Clin. Chem. 2007;53:233-240.
ABSTRACT | FULL TEXT  

Functional MR Imaging of Prostate Cancer
Choi et al.
RadioGraphics 2007;27:63-75.
ABSTRACT | FULL TEXT  

Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men
Wong et al.
JAMA 2006;296:2683-2693.
ABSTRACT | FULL TEXT  

Docetaxel, Estramustine, and 15-Month Androgen Deprivation for Men With Prostate-Specific Antigen Progression After Definitive Local Therapy for Prostate Cancer
Taplin et al.
JCO 2006;24:5408-5413.
ABSTRACT | FULL TEXT  

Potential attenuation of disease progression in recurrent prostate cancer with plant-based diet and stress reduction.
Saxe et al.
Integr Cancer Ther 2006;5:206-213.
ABSTRACT  

Adoption of a plant-based diet by patients with recurrent prostate cancer.
Nguyen et al.
Integr Cancer Ther 2006;5:214-223.
ABSTRACT  

Expression of Variant TMPRSS2/ERG Fusion Messenger RNAs Is Associated with Aggressive Prostate Cancer.
Wang et al.
Cancer Res. 2006;66:8347-8351.
ABSTRACT | FULL TEXT  

Best practice in primary care pathology: review 4
Smellie et al.
J. Clin. Pathol. 2006;59:893-902.
ABSTRACT | FULL TEXT  

Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition
Stephenson et al.
JCO 2006;24:3973-3978.
ABSTRACT | FULL TEXT  

The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:1485-1489.
ABSTRACT | FULL TEXT  

Chronic Administration of Valproic Acid Inhibits Prostate Cancer Cell Growth In vitro and In vivo.
Xia et al.
Cancer Res. 2006;66:7237-7244.
ABSTRACT | FULL TEXT  

Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes Is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment
Ferrari et al.
JCO 2006;24:3081-3088.
ABSTRACT | FULL TEXT  

Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer.
Pantuck et al.
Clin. Cancer Res. 2006;12:4018-4026.
ABSTRACT | FULL TEXT  

Cyclooxygenase-2 Selective Inhibitors and Prostate Cancer: What Is the Clinical Benefit?
DuBois
JCO 2006;24:2691-2693.
FULL TEXT  

Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy
Smith et al.
JCO 2006;24:2723-2728.
ABSTRACT | FULL TEXT  

How Early Is Early: Androgen Deprivation for Prostate-Specific Antigen Relapse in Prostate Cancer
Duchesne et al.
JCO 2006;24:2964-2964.
FULL TEXT  

The emerging roles of DNA methylation in the clinical management of prostate cancer.
Perry et al.
Endocr Relat Cancer 2006;13:357-377.
ABSTRACT | FULL TEXT  

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.
Stephenson et al.
JNCI J Natl Cancer Inst 2006;98:715-717.
ABSTRACT | FULL TEXT  

Therapeutic vaccines for prostate cancer.
Tarassoff et al.
The Oncologist 2006;11:451-462.
ABSTRACT | FULL TEXT  

A prospective study of calcium intake and incident and fatal prostate cancer.
Giovannucci et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:203-210.
ABSTRACT | FULL TEXT  

Retained Seminal Vesicles After Radical Prostatectomy: Frequency, MRI Characteristics, and Clinical Relevance
Sella et al.
Am. J. Roentgenol. 2006;186:539-546.
ABSTRACT | FULL TEXT  

Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy
Slovin et al.
Clin. Cancer Res. 2005;11:8669-8673.
ABSTRACT | FULL TEXT  

Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy
Rosenbaum et al.
Clin. Cancer Res. 2005;11:8321-8325.
ABSTRACT | FULL TEXT  

Active Surveillance for Prostate Cancer: For Whom?
Klotz
JCO 2005;23:8165-8169.
ABSTRACT | FULL TEXT  

Utility of Prostate-Specific Antigen Kinetics in Addition to Clinical Factors in the Selection of Patients for Salvage Local Therapy
Lee and D'Amico
JCO 2005;23:8192-8197.
ABSTRACT | FULL TEXT  

Parameters for Treatment Decisions for Salvage Radiation Therapy
Hayes and Pollack
JCO 2005;23:8204-8211.
ABSTRACT | FULL TEXT  

Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate
Ryan and Small
JCO 2005;23:8225-8231.
ABSTRACT | FULL TEXT  

Geographic and Socioeconomic Variation in the Treatment of Prostate Cancer
Krupski et al.
JCO 2005;23:7881-7888.
ABSTRACT | FULL TEXT  

Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy
Freedland et al.
Clin. Cancer Res. 2005;11:7735-7742.
ABSTRACT | FULL TEXT  

When Prostate Brachytherapy Fails: A Case Report and Discussion
Kadoch et al.
The Oncologist 2005;10:799-805.
ABSTRACT | FULL TEXT  

Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression After Radical Prostatectomy: A Search Database Study
Freedland et al.
JCO 2005;23:7546-7554.
ABSTRACT | FULL TEXT  

Assessing Benefit and Risk in the Prevention of Prostate Cancer: The Prostate Cancer Prevention Trial Revisited
Klein et al.
JCO 2005;23:7460-7466.
ABSTRACT | FULL TEXT  

Predictors of Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation Therapy
Zhou et al.
JCO 2005;23:6992-6998.
ABSTRACT | FULL TEXT  

Postoperative Nomogram Predicting the 10-Year Probability of Prostate Cancer Recurrence After Radical Prostatectomy
Stephenson et al.
JCO 2005;23:7005-7012.
ABSTRACT | FULL TEXT  

Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes
Gade et al.
Cancer Res. 2005;65:9080-9088.
ABSTRACT | FULL TEXT  

Prostate-Specific Antigen Nadir and Cancer-Specific Mortality Following Hormonal Therapy for Prostate-Specific Antigen Failure
Stewart et al.
JCO 2005;23:6556-6560.
ABSTRACT | FULL TEXT  

Is Prostate-Specific Antigen a Valid Surrogate End Point for Survival in Hormonally Treated Patients With Metastatic Prostate Cancer? Joint Research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals
Collette et al.
JCO 2005;23:6139-6148.
ABSTRACT | FULL TEXT  

Preoperative PSA Velocity Is an Independent Prognostic Factor for Relapse After Radical Prostatectomy
Patel et al.
JCO 2005;23:6157-6162.
ABSTRACT | FULL TEXT  

Identifying Patients at Risk for Significant Versus Clinically Insignificant Postoperative Prostate-Specific Antigen Failure
D'Amico et al.
JCO 2005;23:4975-4979.
ABSTRACT | FULL TEXT  

Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy
Freedland et al.
JAMA 2005;294:433-439.
ABSTRACT | FULL TEXT  

PSA Kinetics and Risk of Death From Prostate Cancer: In Search of the Holy Grail of Surrogate End Points
Anscher
JAMA 2005;294:493-494.
FULL TEXT  

Prostate Cancer Clinical Trial End Points: "RECIST"ing a Step Backwards
Scher et al.
Clin. Cancer Res. 2005;11:5223-5232.
ABSTRACT | FULL TEXT  

Androgen Deprivation Therapy for Prostate Cancer
Sharifi et al.
JAMA 2005;294:238-244.
ABSTRACT | FULL TEXT  

Evaluation and Management of Prostate-specific Antigen Recurrence After Radical Prostatectomy for Localized Prostate Cancer
Naito
Jpn J Clin Oncol 2005;35:365-374.
ABSTRACT | FULL TEXT  

The presence of benign prostatic glandular tissue at surgical margins does not predict PSA recurrence
Kernek et al.
J. Clin. Pathol. 2005;58:725-728.
ABSTRACT | FULL TEXT  

2-[18F]Fluoro-2-Deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse after Radical Prostatectomy
Schoder et al.
Clin. Cancer Res. 2005;11:4761-4769.
ABSTRACT | FULL TEXT  

Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial
Rosenbaum et al.
Clin. Cancer Res. 2005;11:4437-4443.
ABSTRACT | FULL TEXT  

Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death
Rubin et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1424-1432.
ABSTRACT | FULL TEXT  

Prediagnostic Plasma Vascular Endothelial Growth Factor Levels and Risk of Prostate Cancer
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1557-1561.
ABSTRACT | FULL TEXT  

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy
Bastian et al.
Clin. Cancer Res. 2005;11:4037-4043.
ABSTRACT | FULL TEXT  

Functionality of Androgen Receptor-Based Gene Expression Imaging in Hormone Refractory Prostate Cancer
Sato et al.
Clin. Cancer Res. 2005;11:3743-3749.
ABSTRACT | FULL TEXT  

20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen et al.
JAMA 2005;293:2095-2101.
ABSTRACT | FULL TEXT  

Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer
Smith et al.
JCO 2005;23:2918-2925.
ABSTRACT | FULL TEXT  

Predictor of Response to Salvage Radiotherapy in Patients with PSA Recurrence after Radical Prostatectomy: the Usefulness of PSA Doubling Time
Numata et al.
Jpn J Clin Oncol 2005;35:256-259.
ABSTRACT | FULL TEXT  

Long-Term Outcomes Among Localized Prostate Cancer Survivors: Health-Related Quality-of-Life Changes After Radical Prostatectomy, External Radiation, and Brachytherapy
Miller et al.
JCO 2005;23:2772-2780.
ABSTRACT | FULL TEXT  

Docetaxel Followed by Hormone Therapy in Men Experiencing Increasing Prostate-Specific Antigen After Primary Local Treatments for Prostate Cancer
Hussain et al.
JCO 2005;23:2789-2796.
ABSTRACT | FULL TEXT  

Metabolic Characterization of Human Prostate Cancer with Tissue Magnetic Resonance Spectroscopy
Cheng et al.
Cancer Res. 2005;65:3030-3034.
ABSTRACT | FULL TEXT  

Stronger Association between Obesity and Biochemical Progression after Radical Prostatectomy among Men Treated in the Last 10 Years
Freedland et al.
Clin. Cancer Res. 2005;11:2883-2888.
ABSTRACT | FULL TEXT  

Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes
Lotan et al.
JCO 2005;23:1911-1920.
ABSTRACT | FULL TEXT  

Pattern of Prostate-Specific Antigen (PSA) Failure Dictates the Probability of a Positive Bone Scan in Patients With an Increasing PSA After Radical Prostatectomy
Dotan et al.
JCO 2005;23:1962-1968.
ABSTRACT | FULL TEXT  

Advances in Radiation Therapy: Conventional to 3D, to IMRT, to 4D, and Beyond
Bucci et al.
CA Cancer J Clin 2005;55:117-134.
ABSTRACT | FULL TEXT  

Randomized Controlled Trial to Evaluate Radiotherapy {+/-} Endocrine Therapy Versus Endocrine Therapy Alone for PSA Failure after Radical Prostatectomy: Japan Clinical Oncology Group Study JCOG 0401
Yokomizo et al.
Jpn J Clin Oncol 2005;35:34-36.
ABSTRACT | FULL TEXT  

Inhibitory Effect of Antagonists of Bombesin and Growth Hormone-Releasing Hormone on Orthotopic and Intraosseous Growth and Invasiveness of PC-3 Human Prostate Cancer in Nude Mice
Stangelberger et al.
Clin. Cancer Res. 2005;11:49-57.
ABSTRACT | FULL TEXT  

Nuclear Factor-{kappa}B Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer
Fradet et al.
Clin. Cancer Res. 2004;10:8460-8464.
ABSTRACT | FULL TEXT  

Gonadotropin-releasing hormone and its receptor in normal and malignant cells
Harrison et al.
Endocr Relat Cancer 2004;11:725-748.
ABSTRACT | FULL TEXT  

Health-Related Quality of Life, Satisfaction, and Economic Outcome Measures in Studies of Prostate Cancer Screening and Treatment, 1990-2000
McNaughton-Collins et al.
J Natl Cancer Inst Monogr 2004;2004:78-101.
ABSTRACT | FULL TEXT